DocMorris Sees Revenue Surge in First Nine Months of 2025

DocMorris AG reports a notable 9.5% increase in total revenue for the first nine months of 2025, reaching CHF 854.3 million. This growth is evident despite discontinuing the Zur Rose brand in Germany at the end of 2024. The company's non-prescription (non-Rx) business in Germany has seen expansion, with TeleClinic's revenue climbing over 140%, highlighted by its recognition as one of the "World's Top HealthTech Companies 2025" by TIME Magazine. Furthermore, the full rollout of the AI-based DocMorris health companion marks a strategic enhancement.

The prescription (Rx) segment experienced a significant 37.9% rise in external revenue over the same period, with a 9.2% increase in Q3 alone. DocMorris continues to streamline its operations, consolidating e-commerce activities in Germany and Europe under newly appointed Chief Commercial Officer Andrea Skersies. The company's outlook remains positive, confirming its 2025 targets and aiming for EBITDA breakeven in 2026.